Dr. Arpeet Shah

Yeah, and this is why when we look at national Medicare data, we see such high failure rates with BPH procedures. It's because we're intervening too late, right? We're intervening when the bladder has already failed.

Yeah, and this is why when we look at national Medicare data, we see such high failure rates with BPH procedures. It's because we're intervening too late, right? We're intervening when the bladder has already failed.

And to expect that after somebody's in heart failure, if we stent them, that their heart's going to get back to normal is, you know, a very common sense that it's not going to get better just with that. And so early intervention is important.

And to expect that after somebody's in heart failure, if we stent them, that their heart's going to get back to normal is, you know, a very common sense that it's not going to get better just with that. And so early intervention is important.

And to expect that after somebody's in heart failure, if we stent them, that their heart's going to get back to normal is, you know, a very common sense that it's not going to get better just with that. And so early intervention is important.

The other thing, you know, we actually published a study on this is that we looked at all of our patients who are following up, satisfied on medical therapy for BPH. And I think medical therapy works for a lot of people. But we did UroCuffs on them and 62% had abnormal UroCuffs. So, you know, even these are patients who are coming in saying they're satisfied on medication.

The other thing, you know, we actually published a study on this is that we looked at all of our patients who are following up, satisfied on medical therapy for BPH. And I think medical therapy works for a lot of people. But we did UroCuffs on them and 62% had abnormal UroCuffs. So, you know, even these are patients who are coming in saying they're satisfied on medication.

The other thing, you know, we actually published a study on this is that we looked at all of our patients who are following up, satisfied on medical therapy for BPH. And I think medical therapy works for a lot of people. But we did UroCuffs on them and 62% had abnormal UroCuffs. So, you know, even these are patients who are coming in saying they're satisfied on medication.

So getting that objective data to them is just really important.

So getting that objective data to them is just really important.

So getting that objective data to them is just really important.

Yeah, for our patients, all of our new patients who have BPH automatically get a, through email, text, get a copy of our BPH booklet, which is just an introductory booklet on all of the tests that we have diagnostic, and then a quick blurb, short paragraph on all the procedures that are out there so they can have some early education on it. But really, we wait until the objective is

Yeah, for our patients, all of our new patients who have BPH automatically get a, through email, text, get a copy of our BPH booklet, which is just an introductory booklet on all of the tests that we have diagnostic, and then a quick blurb, short paragraph on all the procedures that are out there so they can have some early education on it. But really, we wait until the objective is

Yeah, for our patients, all of our new patients who have BPH automatically get a, through email, text, get a copy of our BPH booklet, which is just an introductory booklet on all of the tests that we have diagnostic, and then a quick blurb, short paragraph on all the procedures that are out there so they can have some early education on it. But really, we wait until the objective is

data is gotten. So until we figure out their size, shape, and flow rates, and then you can introduce the procedures that will actually work, that will benefit a patient. I mean, there's no reason to, you know, offer a Urolift, in my opinion, on, you know, somebody with a very, very large prostate.

data is gotten. So until we figure out their size, shape, and flow rates, and then you can introduce the procedures that will actually work, that will benefit a patient. I mean, there's no reason to, you know, offer a Urolift, in my opinion, on, you know, somebody with a very, very large prostate.

data is gotten. So until we figure out their size, shape, and flow rates, and then you can introduce the procedures that will actually work, that will benefit a patient. I mean, there's no reason to, you know, offer a Urolift, in my opinion, on, you know, somebody with a very, very large prostate.

And so you don't want to introduce it too early where patients, you know, are tied to a particular therapy that just won't work for them. We don't want to offer, you don't want to, you know, kind of withhold that information either. It's just kind of slowly introducing that concept.

And so you don't want to introduce it too early where patients, you know, are tied to a particular therapy that just won't work for them. We don't want to offer, you don't want to, you know, kind of withhold that information either. It's just kind of slowly introducing that concept.

And so you don't want to introduce it too early where patients, you know, are tied to a particular therapy that just won't work for them. We don't want to offer, you don't want to, you know, kind of withhold that information either. It's just kind of slowly introducing that concept.